

2024

2024 Interim Results Presentation

Aug 2024

INNOVATION

China's Leading Innovative Pharmaceutical Enterprise

R&D Capabilities



8

R&D platforms



5

R&D centres located in
China & the U.S.



~2000

R&D professionals



~300

R&D projects



Manufacturing Capabilities

- **10+** Production bases for pharmaceutical products
- Nano formulation production capacity of **20M** doses/year; Biologics fermentation capacity of **40,000L**
- Chemical drugs production capacity of OSD **~30B** tablets/year, production capacity of injection **~3B** doses/year
- mRNA vaccines: GMP-compliant production plant has been built
- siRNA: pilot scale production lines has been built; commercial scale production line is under construction



Commercialisation Capabilities

- **10000+** professional sales personnel
- **35000+** medical institutions, and **350000+** drug stores
- Products exported to **110+** countries; overseas marketing centers established in the U.S., Germany and Brazil

2024 Interim Updates

Regulatory Updates

2 new drug approvals:

- Mingfule (AIS): The first of its kind product approved in China, it is the second indication
- Enshuxing (PD-1): The first indication for advanced cervical cancer approved

1 drug approval submission accepted:

- Butyrate Clevidipine injectable emulsion: For the treatment of hypertensive emergencies/urgency

5 generic drugs approved:

-2 first generic drugs of its kind

- Roxadustat capsules
- Palbociclib tablets



Results & Shareholder Return

Results:

- Revenue increased by **1.3%** to **RMB16.28 B**

Shareholder Return:

- Distribute an interim dividend of **HK16** cents per share, representing **14.3%** year-on-year increase
- Repurchased **HK\$387M** during 1H'2024, will further repurchase the total amount up to **HK\$1,000M** of shares
- The Company's total return to shareholders will reach **HK\$3,285M**

Major Clinical Trials Progress

25 IND approvals :

- **China 22:** CAR-T, RSV vaccine etc.
- **North America 3:** of which SYS6023 (ADC) obtained approval in china and US

6 Additional Pivotal trials:

- Secukinumab injection
- SYHX1901 tablets
- Sirolimus for injection (albumin-bound)
- Aprepitant injection
- Pregabalin extended-release tablets
- Pilocarpine hydrochloride eye drops

Contents

01

Financial Highlights

02

Business Review

03

R&D Capabilities

04

Pipeline

05

BD & ESG



01

**Financial
Highlights**


Financial Highlights

In: RMB' M


	2024 1H	2023 1H	Change
Revenue	16,284	16,080	+1.3%
Gross profit	11,655	11,238	+3.7%
Gross profit margin	71.6%	69.9%	+1.7%
R&D expenses	2,542	2,304	+10.3%
Underlying profit attributable to shareholders*	3,217	3,162	+1.7%
Reported profit attributable to shareholders	3,020	2,967	+1.8%
Basic earnings per share (<i>RMB cents</i>)			
• Based on underlying profit attributable to shareholders	27.17	26.59	+2.2%
• Based on reported profit attributable to shareholders	25.51	24.95	+2.2%

Note


Underlying profit attributable to shareholders, a non-HKFRS measure, represents profit before taking into account fair value changes on financial assets measured at fair value through profit or loss and employee share-based compensation expense.



Underlying profit attributable to shareholders



Reported profit attributable to shareholders



Revenue

Revenue by product category

	2024 1H	2023 1H	Change
Finished drugs	13,549	12,934	+4.8%
Bulk vitamin C	984	1,040	-5.4%
Bulk antibiotics	871	930	-6.4%
Functional food and others	880	1,177	-25.2%

In: RMB' M

Revenue by therapeutic area

	2024 1H	2023 1H	Change
Nervous system	5,236	4,553	+15.0%
Oncology	2,683	2,988	-10.2%
Anti-infectives	2,307	2,143	+7.7%
Cardiovascular	1,229	1,287	-4.5%
Respiratory system	756	874	-13.5%
Digestion & metabolism	647	416	+55.4%
Others	691	638	+8.3%

Note: Certain percentage changes of financial figures contained in this material are calculated based on the corresponding financial figures in RMB for two periods/years, rounded to the nearest thousand. Therefore, the percentage changes listed in certain tables may differ from those calculated based on the financial figures in RMB for two periods/years, which are presented in million.

Operating Profit

	2024 1H	2023 1H	Change	2024 1H OPM	2023 1H OPM	Change
Finished drugs	3,488	3,192	+9.3%	25.7%	24.7%	+1.0%
Bulk vitamin C	67.6	67.6	+0.1%	6.9%	6.5%	+0.4%
Bulk antibiotics	186	71.4	+160.5%	21.4%	7.7%	+13.7%
Functional Food and Others	175	331	-47.1%	19.9%	28.1%	-8.2%

In: RMB' M


Note: certain percentage changes of financial figures contained in this material are calculated based on the corresponding financial figures in RMB for two periods/years, rounded to the nearest thousand. Therefore, the percentage changes listed in certain tables may differ from those calculated based on the financial figures in RMB for two periods/years, which are presented in million.



02

Business Review

Finished Drugs Overview by Therapeutic Areas



Nervous system

- Major products: NBP (butylphthalide soft capsules, butylphthalide and sodium chloride injection), Mingfule-AIS (recombinant human TNK tissue-type plasminogen activator for injection), Shuanling (pentoxifylline extended-release tablets, pentoxifylline injection), Oulaining (oxiracetam capsules, oxiracetam for injection), Enxi (pramipexole dihydrochloride tablets), Enlwei (lacosamide injection, lacosamide tablets), and Oushuan (paliperidone Extended-release tablets)

Oncology

- Major products: Duomeisu (doxorubicin hydrochloride liposome injection), Jinyouli (PEG-rhG-CSF injection), Keaili (paclitaxel for injection (albuminbound)) Duoenda (mitoxantrone hydrochloride liposome injection), Duoenyi (irinotecan hydrochloride liposome injection), Jinlitai (Narlumosbart injection), Copiktra (duvelisib capsules) and Geruite (lenvatinib mesilate capsules)

Anti-infective

- Major products: Anfulike (amphotericin B cholesteryl sulfate complex for injection), Shuluoke (meropenem for injection), Nuomoling (amoxicillin capsules), Xianqu (Ceftriaxone Sodium for Injection), Xianwu (Cefazolin Sodium for Injection), Zhongnuo Lixin (Cefuroxime Sodium For Injection), and Weihong (azithromycin tablets/capsules/enteric-coated tablets, azithromycin for injection)

Cardio-vascular

- Major products : Xuanning (levamlodipine maleate tablets and dispersible tablets), Mingfule - MI (recombinant human TNK tissue-type plasminogen activator for injection), Encun (clopidogrel bisulfate tablets), Daxinning (dronedarone hydrochloride tablets), Abikang (Aspirin enteric-coated tablets), Yishuning (nifedipine controlled-release tablets), and Meiluolin (Ticagrelor tablets)

Respiratory system

- Major products: Yiluoda (nintedanib capsules), Qixin (oseltamivir phosphate capsules), Qixiao (arbidol hydrochloride tablets), Nuoyian (montelukast sodium tablets/chewable tablets), Zhongnuo Like (ambroxol hydrochloride oral solution) and Zhongnuoping (ambroxol hydrochloride extended-release tablets)

Digestion & metabolism

- Major products : Debixin (omeprazole enteric capsules/tablets/injections), Linmeixin (glimepiride dispersible tablets), Shuanglexin (metformin hydrochloride tablets/extended-release tablets), Xinweiping (acarbose tablets), and Obeituo (Esomeprazole magnesium enteric-coated capsules)

Others

- Major products: Oubida (Apgumilast tablets), Gujie (Tofacitib citrate sustained release tablets), Gubang (alendronate sodium tablets/enteric tablets), Xianpai (omeprazole sodium for injection) and Qimaite (tramadol hydrochloride tablets)

Key Products Overview



NBP

Butylphthalide soft capsules and injections

- 1st Class 1 new drug of cardio-cerebrovascular field in China
- Price cut after negotiation improves affordability and accessibility, benefiting more patients
- Significant growth in OTC and E- channels



Xuanning

Levamlodipine maleate tablets and dispersible tablets

- The first Chinese innovative drug fully approved by the U.S. FDA
- Has served 50 million hypertensive patients in China
- Recommended by authoritative guidelines such as “China Hypertension Prevention Guide” and “Guidelines for Rational Drug Use of Hypertension”



Anfulike

Amphotericin B cholesteryl sulfate complex for injection

- Exclusive product , obtained marketing approval by NMPA in March 2021
- was included in the NRDL in December 2021 , covered approx.1,600 hospitals
- has a unique drug uptake and release mechanism, significantly decrease nephrotoxicity and increase dosage



Mingfule

Recombinant human TNK tissue-type plasminogen activator for injection

- For thrombolytic therapy in patients with acute ischemic stroke within 4.5h
- For thrombolysis in patients with acute myocardial infarction within 6h
- Preferred thrombolytic drug recommended by authoritative guidelines such as “Chinese Expert Consensus on Pre-hospital Thrombolysis”, “2023 SIGN Clinical Management Guide”, and “Chinese Guidelines for the Diagnosis and Treatment of Acute Ischemic Stroke”


Key Products Overview



Duomeisu

Doxorubicin Hydrochloride liposome injection

- Largest market share in China
- The first player who passed consistency evaluation



Jinyouli

PEG-rhG-CSF injection

- The 1st long-acting white blood cell booster drug in China
- The provincial alliance collects products, and more patients will benefit after the price reduction.



Duoenda

Mitoxantrone hydrochloride liposome injection

- Obtained marketing approval in January 2022, exclusive new preparation worldwide
- Included in the NRDL in Dec. 2023
- Various clinical trails undergoing, blockbuster potential



Duoenyi

Irinotecan hydrochloride liposome injection

- First generic drug in domestic market in Sep. 2023
- Recommended by domestic and foreign authoritative guidelines (NCCN/CSCO/CACA)



Jinlitai

Narlumosbart for injection

- The first IgG4 subtype fully human monoclonal antibody against RANKL obtaining marketing approval in the world
- New indications of tumor bone metastasis and osteoporosis are under development

Bulk Product Business, Functional Food and Others

01

Bulk vitamin C

- Major products: vitamin C, vitamin C - sodium, vitamin C - calcium and granular vitamin C
- Sales of vitamin C products decreased by 5.4% to RMB984 million due to the decline in market demand

02

Bulk antibiotics

- Major products: 7-ACA (intermediate), cefazolin sodium, penicillin potassium, penicillin sodium, azithromycin, and ertapenem sodium
- Sales of antibiotic products decreased by 6.4% to RMB871 million, which was mainly affected by the decrease in demand in overseas markets

03

Functional food and others

- Revenue of the functional food and others decreased mainly affected by the decrease in price of caffeine products
- The overall market share of caffeine products over 60%



03

R&D Capability



R&D Centre

- 5 R&D centres located in China & the U.S.
- R&D expenses in 2024 1H: RMB2.54B



Technology Platform

- 8 national science & technology qualifications
- 2 national key labs
- 8 R&D technology platforms



Project under Development & IPs

- Approx.300 projects under development (approx. 130 innovative drug projects)
- 1948 IPs applications
- 951 IPs authorised




Science Projects & Government Support

- 90 national projects
- RMB 928M government grant support
- 8 national prizes


Innovative R&D Platforms

Nano-formulation



- Mitoxantrone liposome
- Albumin-bound docetaxel
- Paclitaxel cationic liposome
- Cisplatin micelle

mRNA vaccine




- Covid-19 mRNA vaccine, RSV mRNA vaccine and various preventive and therapeutic vaccines

siRNA




- PCSK9 siRNA and other chronic disease drugs

ADC




- CLDN18.2 ADC
- Nectin-4 ADC
- EGFR-ADC

Antibody & Fusion protein




- JMT103 (RANKL)
- JMT101 (EGFR)
- JMT106 (GPC3/IFN)

CAR-T




- SYS6020 (CAR-T anti-BCMA)

Small molecule



- Prugliptin (DPP-4)
- Amuxetine
- SYHX1901 (Syk-Jak)
- SYHA1813 (VEGFR/CSF1R)

Long-acting injection



- Octreotide Long-acting injection
- Paliperidone injection
- Leuprorelin microsphere injection

Note: only shows the representative products on each platform

Nano-formulation Platform



Nano-formulation development and manufacturing platform



Novel drug carrier design

- Invented Albumin nanoemulsion
- Developed new cationic materials and new delivery system

Novel drug delivery technology

- Invented ammonium salt gradient method of sulfobutylether- β -cyclodextrin and 5-sulfosalicylate
- Cholesterol PEGylation modification method and post single layer PEGylation

Novel preparation method

- Invented single-phase solution lyophilization technology, O/W type Emulsification technology, crossflow mixing technology, continuous flow reaction technology, etc.
- Invented bottom up nanocrystal preparation technology, enabling continuous production

Novel Industrialized production technology

- Invented continuous flow technology, employing linear amplifier, overcome barriers to industrialized production
- Illustrated that all nano drugs are able to be prepared by permutation and combination of four key processes



Nano-formulation assessment system



Particle characterisation method

- Developed nano-formulation assessment technology for liposome, albumin nanoparticles, emulsion, micelles, etc.

PK determination method

- Established multiple PK determination methods for nano drugs including liposome, albumin nanoparticle, micelles etc.

Mature animal screening models

- Established multiple animal disease model for efficacy assessment
- Established animal models for evaluating ABC phenomenon, CARPA response and HFS, enabling quick screening

Particle characterisation technique guided in vivo PK, PD, TOX evaluation

- Illustrated influence of drug release rate of liposome, mode of administration and animal model on ABC phenomenon
- Detailed study of CARPA and HFS laid the foundations for rational design of nanoparticles

The largest R&D and industrialization base for Nano- Formulation

mRNA Vaccine platform

1 Advantages of antigen design

- Mutation prediction platform
- The combination of bioinformatics and structural biology to obtain effective epitopes
- Superior immunogenicity from site-specific mutation of antigen

2 mRNA vaccine design

- Base modification, UTR screening, codon optimization and structural elements inclusion
- Structural energy optimization to enhance antigen expression

3 Manufacturing capabilities

- Manufacturing capabilities of CSPC
- Top tier LNP R&D platform
- Manufacturing capacity reaches to 1.5 billion doses per year

4 Excellent safety profile

- No observed SAE in clinical trials
- Excipients proven to be low toxicity by launched products
- Base modification mitigates innate immunogenicity
- Formulation ensures long-term stability

5 Streamlined CMC Strategy

- One-step API manufacturing process
- API purification process: > 99% purity
- Highly scalable LNP manufacturing process
- Short turnaround time: ~2 days

6 Highly expandable platform

- Each individual component can be continuously upgraded
- Expansion from linear mRNA to circRNA; from liver-target delivery to extrahepatic delivery
- From preventive to therapeutic application; from vaccine to CGT



1 HTS screening platform

- Rational sequence design based on bioinformatics and experienced scientists
- Comprehensive in vitro and in vivo PK/PD characterization

2 CMC platform

- Build strong oligonucleotides CMC platform based on QbD strategy
- Develop liquid synthesis technology

3 Manufacturing capabilities

- Manufacturing capabilities of CSPC
- Two GMP-compliant production lines have been built

4 Excellent safety profile

- Build off-target risk assessment platform
- Chemical modification to mitigate immunogenicity
- Long-term stability

5 Nucleotides building blocks

- Develop novel building blocks
- Develop Galnac molecule with in-house IP
- Scalable building blocks manufacturing technology

6 Highly expandable platform


- Each individual component can be continuously upgraded
- Integrated manufacturing capabilities for building blocks, API and drug products



1 Payload platform

Multiple payload types for different cancer treatment mechanism of actions

- microtubule inhibitor
- Topoisomerase inhibitors
- Protein degrading agent
- DNA alkylating agent
- DNA repair inhibitors
- Immunoagonists
- Immunosuppressants
- hormone



2 Linker platform

Various linker design for stability, PK and other purpose beneficial for ADCs

- Hydroflex platform ensures hydrophilicity, stability and PK
- TMEC the TME payload released platform overcomes the problem of non-internalize targets
- Novel ESIM self-immolation platform enhances drug release efficiency.
- The HighDAR platform makes it possible to use low potent payloads in ADC

3 Conjugation platform

Including mainstream conjugation technology and proprietary site-specific conjugation technology with IP rights.

- Conventional lysine and cysteine conjugation platforms
- SmartQTag enzyme-mediated conjugation technology
- Glycan-engineered site-specific conjugation technology

4 New molecular entity

Multiple ADC drug molecules provide more clinical treatment options, and overcome the drug resistance of current existing therapies.

ADC Antibody-drug conjugate	ISAC Immune-stimulating antibody conjugate	DAC Degradable-antibody conjugate	dpAC Dual-payload antibody conjugate	CA-ADC Conditional-activated-ADC	Bs-ADC Bispecific-ADC	PDC Peptide-drug conjugate
Cytotoxin	Immune-stimulator	Protein degrader	Synthetic lethal	pH-activated mAb	Dual-epitope	Peptide

Antibody & Fusion protein Platform

Antibody-interferon fusion protein platform

Structural advantages

- **Synergistic** binding effect when targeting the same cell
- **Smaller** molecular weight (smaller than that of conventional antibodies)

Safer impurities

- The activity of interferon-containing impurities is **far lower** than that of conventional bispecific antibodies.
- No serious safety risk of interferon-containing impurities from the production process


Stronger target selectivity

- Limited binding activity to receptors on TAA – cells, demonstrating a **wider therapeutic window**
- The optimizing of interferon mutation further improves **target selectivity**


More stable product

- More efficient in CMC development
- Significantly reduces the interferon breakage during the production and in vivo, resulting in **high yield** and **low risk**

- ✓ High expandability : quickly forms new molecules
- ✓ Better safety profile : much safer than interferon
- ✓ More effective in tumor killing: much stronger than interferon
- ✓ remodels the tumor immune micro environment: enhances immune cell infiltration and MHC1 presentation
- ✓ Lower production cost : high efficiency, low toxicity, and simple process




CD47-targeting bifunctional fusion protein platform




- ✓ Does not bind to TAA-/CD47+cells, including erythrocytes, platelets, etc.
- ✓ TAA-dependency enhances CD47 competitive binding
- ✓ High expandability: various types of tumor-targeting antibodies could be used as the left-arm
- ✓ Wider safety window
- ✓ Lower molecular weight, better suits solid tumors
- ✓ Simple production process
- ✓ Possession of intellectual property right

Mechanism



CAR-T Platform



mRNA-LNP CAR-T

Lower cost

The cost of mRNA-LNP is much lower than virus vector

Process

mature mRNA-LNP and T cell production process

Safety

it has no risk of tumorigenesis associated with genomic integration, and significantly reduces adverse effects, notably CRS.

High positive rate


our innovation platform boasts superior cell viability and a higher percentage of CAR-positive cell (90%)

expansibility

Can be expanded to other immune cells or in vivo treatments

clinical

SYS6020 is the world's first mRNA-LNP-based approved cell therapy therapy for clinical trials



04

Pipeline

Candidates under Clinical Trial Stage



PhI



PhII(POC)



PhIII pivotal trial



NDA

NBL-012 IL23-P19	NBL-015 CLDN18.2 mAb	NBL-020 TNFR2
NBL-028 CLDN6-CD137	SYS6002 Nectin-4 ADC	SYS6010 EGFR ADC
SYS6011	JMT203 GFRAL	JMT202 FGFR1c/βkloth
SYHX1903 CDK9	SYHA1811 BTK	SYHA1805 FXRs
SYHX2009 NTRK/ROS1	SYH2045 PRMT5	SYHA1815 FGFR/RET
SYH2038 SOS1	SYHX2001 PRMT5	SYHX2005 FGFR4
Cisplatin micelle	SYH2051 ATM	SYH2043 CDK2/4/6
Nanomedicine SYHA1908	SYH2039 MAT2A	SYH2053 PCSK9 siRNA
SYS6020 BCMA-CarT	SYS6016 RSV mRNA	SYS6023 ADC

CLDN18.2 ADC	CM326 TSLP
ALMB0166 Cx43i mAb	ALMB0168 Cx43s mAb
JMT601 CD20/CD47	SYHA1813 VEGFR/CSF1R
Simmitinib TKI	SYHA1402 ARi
Amuxetine 5-HT/NE	Octreotide long- acting injection
Alprostadil liposome	Paclitaxel cationic liposome

JMT101 EGFR mAb	CM310 IL4R
KN026 Her2 BsAb	TG103 Fc-GLP1
Pertuzumab	Ulsinumab
DP303C HER2 ADC	Secukinumab
JMT103 bone metastasis	Semaglutide injection
Albumin-bound Paclitaxel II	Pregabalin extended-release tablets
Mitoxantrone hydrochloride liposome (NPC)	Pilocarpine hydrochloride eye drops
Daunorubicin cytarabine liposome	Aprepitant Injection
Albumin-bound Docetaxel	SYHX1901 JAK/SYK
Albumin-bound Sirolimus	

Omalizumab biosimilar
Batoclimab
Meloxicam nanocrystal injection
Irinotecan liposome (US)
Amphotericin B Liposome (China, US)
Clevipidine injectable emulsion
DBPR108 DDP4

Biological Agents
 Chemical Drugs
 New formulations

Pepline--Biological Agents

2 commercialized , **2** filed BLA , **8** under pivotal trial stage , **>17** under clinical development stage

——Including various forms of drugs such as monoclonal antibody medicines, cell therapies, and Antibody-Drug Conjugates (ADCs).

Major candidates	Target	Type	PhI	PhII	PhII/III	NDA/BLA	Launch
JMT103	RANKL	mAb	Launch: GCTB; under clinical development: bone metastasis (PhIII) 、 osteoporosis				★
SYSA1802	PD-1	mAb	Launch: Advanced cervical cancer; IL cervical cancer (PhIII)				★
Batoclimab	FcRn	mAb	Myasthenia gravis(MG)				
JMT101	EGFR	mAb	NSCLC				
TG103	GLP-1	mAb	Obesity, Diabetes				
CM310	IL-4	mAb	Asthma、 COPD				
CM326	TSLP	mAb	Asthma、 COPD				
ALMB0166	CX43 Antagonist	mAb	Spinal cord injury, AIS				
ALMB0168	CX43 Agonist	mAb	Bone cancer, cancer bone metastasis				
NBL-012*	IL-23p19	mAb	Psoriasis、 HS、 IBD				
NBL-020*	TNFR2	mAb	Advanced tumors				
SYS6011	Undisclosed	mAb	Advanced tumors				
NBL-015*	Claudin 18.2	mAb	Advanced tumors				
JMT203	GFRAL	mAb	Cancer cachexia				
JMT202	FGFR1c/βklotho agonist	mAb	Lower triglyceride (TG) levels in patients with hypertriglyceridemia				

*approval for US & china

Pepline--Biological Agents

Major candidates	Target	Type	PhI	PhII	PhII/III期	NDA/BLA	Launch
Omalizumab	IgE	Bio-similar	CSU、Asthma				★
Ulsinumab	IL-12/IL-23	Bio-similar	Psoriasis				
Secukinumab	IL-17A	Bio-similar	Psoriasis				
Pertuzumab	HER2	Bio-similar	Breast cancer				
KN026	HER2	BsAb	2L Gastric cancer (PhIII) , 1L breast cancer (PhIII) ,				
JMT601*	CD47/CD20	BsAb	NHL& multiple hematologic tumors				
NBL-028*	CLDN6-CD137	BsAb	Advanced tumors				
DP303c	HER2 ADC	ADC	Breast cancer				
SYSA1801*	CLDN18.2 ADC	ADC	Gastric cancer				
SYS6002*	Nectin-4 ADC	ADC	Advanced tumors				
SYS6010*	EGFR ADC	ADC	Advanced tumors				
SYS6023*	Undisclosed	ADC	Advanced tumors				
SYS6020	BCMA-CART	CAR-T	multiple myeloma				
SYS6016	RSV -pre F	Preventive vaccine (mRNA)	prevention of lower respiratory tract diseases caused by RSV infections				

Pepline--New Formulations

2 commercialized , **3** filed NDA, **5** under pivotal trial stage , **>5** under clinical development stage

——Including various forms of drugs such as liposomes, albumin and nanocrystals

Major candidates	Type	PhI	PhII	PhII/III期	NDA/BLA	Launch
Mitoxantrone hydrochloride liposome injection	New formulation	Launch:PTCL; under clinical development: NPC (PhIII) 、 Diffuse large B lymphoma				★
Irinotecan liposome injection*	New formulation	Launch:pancreatic cancer; (Filed for FDA for approval)				★
Meloxicam nanocrystal injection	New formulation	Moderate-to-severe pain				
Amphotericin B Liposome*	New formulation	Invasive fungal infection (Filed for approval in NMPA and FDA)				
Clevidipine injectable emulsion	New formulation	Hypertension emergency				
Daunorubicin cytarabine liposome	New formulation	Elderly newly diagnosed with high-risk secondary AML				
Albumin-bound Paclitaxel II	New formulation	Breast cancer				
Docetaxel for injection (albumin-bound)	New formulation	Gastric cancer (PhIII) 、 pancreatic cancer (PhIII)				
Sirolimus for injection (albumin-bound)	New formulation	Advanced tumors				
Aprepitant injection	New formulation	Prevention of nausea and vomiting after surgery				
Alprostadil liposome	New formulation	Vasodilation				
Octreotide long-acting injection	New formulation	Acromegaly、 Gastrointestinal Pancreatic Neuroendocrine Tumor				
Paclitaxel cationic liposome	New formulation	Advanced tumors				
Cisplatin micelle	New formulation	Advanced tumors				
SYHA1908 for injection	New formulation	Advanced tumors				

*approval for US & china

Pepline--Small Molecule Drugs


1 filed NDA , **4** under pivotal trial stage , > **10** under clinical development stage

Major candidates	Target	Type	PhI	PhII	PhII/III期	NDA/BLA	Launch	
DBPR108	DPP-4	Small molecule	T2DM					
Semaglutide injection	GLP-1	Polypeptide	T2DM (PhIII) 、 Obesity,					
Pilocarpine hydrochloride eye drops	AChR	Small molecule	Presbyopia					
Pregabalin extended-release tablets	γ-GABA analogue	Small molecule	Neuropathic pain associated with diabetic peripheral neuropathy					
SYHX1901	Syk-Jak	Small molecule	Psoriasis (PhIII), vitiligo and alopecia areata					
Amuxetine hydrochloride enteric tablets	5-HT, SNDRI	Small molecule	Anti-depressant					
Simmitinib tablets	FGFR/KDR	Small molecule	Gastric cancer, cholangiocarcinoma, SQCC					
SYHA1813	VEGFR/CSF1R	Small molecule	Advanced solid tumor					
SYHX2005	FGFR4	Small molecule	Advanced solid tumor					
SYH2043	CDK2/4/6	Small molecule	Breast cancer					
SYH2045	PRMT5	Small molecule	Advanced tumor					
SYH2051	ATM	Small molecule	Advanced tumor					
SYH2039	MAT2A	Small molecule	Advanced tumor					
SYHA1805	FXR Agonist	Small molecule	NASH(MASH)					
SYH2053	PCSK9-siRNA	SiRNA	FH, Mixed hyperlipidemia					

Pipeline Products Launch Plan

Expected about 50 New Drugs /Indications to be approved in coming 5 years

- Vaccine
- Biological Agents
- Chemical Drugs
- New formation
- Non-Chinese region



Major Data Release Plan for 2024

7 major datas published

JMT103-bone metastasis-PhIb	ASCO	online publication
simmitinib-tumor-PhI	ASCO	poster
SG001-cervical cancer-PhII	ASCO	poster
SYS6002-solid tumor-PhI	ASCO	poster
Docetaxel (albumin-bound) -Gastric cancer-PhII	ASCO	online publication
Irinotecan liposome-1L pancreatic cancer-PhII	ASCO	poster
JMT101 co osimertinib-EGFR 20ins NSCLC-PhII	ELCC	mini-oral

5 datas were Accepted

SYHA1813-Brain glioma-PhI	ESMO	mini-oral
KN026 combined therapy -Gastric cancer-PhII	ESMO	poster
CM310-Moderate and severe asthma-PhII	ERS	poster
SYHX1901-Moderate and severe psoriasis--PhII	EADV	poster
NBL-012-health subjects-PhI	EADV	poster

9 research results were published

SG001- cervical cancer-Ib	Cancer Communications	IF 20.1
Mingfule-AIS-4.5~24h (TRACE-3)	The New England Journal of Medicine	IF96.2
SYS6006-COVID 19-PhI and PhII	Vaccine	IF5.5
SYS6006-COVID 19 vaccine-PhIII	Emerging Microbes&Infections	IF13.2
SYS6006-COVID 19 vaccine-2 or 3 doses	MedicalVirology	IF12.7
DBPR108 -T2DM-PhIII	Diabetes, Obesity & Metabolism,	IF 5.8
Mingfule rhTNK-tPA-Acute ST-segment elevation myocardial infarction-PhII	Chinese Medical Journal,	IF6.1
TG103-Obesity-PhIb	BMC Medicine	IF 9.3

In the plan

JMT101 CO osimertinib-EGFRSensitive mutation-PhII
Paclitaxel cationic liposome CO therapy-Hepatic metastatic tumor-IIT
Mitoxantrone hydrochloride liposome injection-HNSCC-PhI
DP303c-PhI
Mitoxantrone hydrochloride liposome injection-ENKTCL-PhI/II
CM310-Moderate and severe asthma-PhII
Amuxetine hydrochloride enteric tablets-Anti-depressant-PhII

Common Generics Launch Plan

20 generic drugs will be approved during the years 2024-2025; Additionally, approximately **30** projects currently in the pharmaceutical research phase, with plans to be approved before 2027

2024

Dapagliflozin tablets

Digestion & Metabolism ✓

Rabeprazole sodium enteric-coated tablets (10mg) ✓

Digestion & Metabolism

Olaparib tablets ✓

Oncology

Palbociclib tablets (125mg) ✓

Oncology

Lenalidomide capsules (5mg 10mg) ✓

Digestion & Metabolism

Peramivir injection (150mg/15ml) ✓

Anti-infective

Roxadustat capsules ✓

Others

Dexrazoxane for injection

Others

Aprepitant injection

Others

Note: Rabeprazole and Lenalidomide capsules are belong to the Increasing specifications

2025

Peramivir Injection (300mg/60ml)

Anti-infective

Regorafenib tablets

Oncology

Ilaprazole enteric-coated tablets

Digestion & Metabolism

Tacrolimus Sustained-Release Capsules

Autoimmunity

Oseltamivir phosphate for oral suspension

Anti-infective

Mesalazine enteric-coated tablets

Autoimmunity

Vonorazone fumarate tablets

Digestion & Metabolism

Adenosine cobalamin capsules

Others

Palbociclib tablets (25mg)

Oncology

Pentoxifylline sustained-release tablets

Cardiovascular and cerebrovascular

Terezolamide phosphate tablets

Anti-infective



05

BD&ESG

BD Strategic Layout and Path of Advancement

Focusing on strategic domains, deepening BD strategies, and establishing an international BD ecosystem

BD Product Positioning: Aligning closely with clinical needs, emphasizing clinical benefits, grasping international cutting-edge technology and product trends, strengthening areas of group advantage, focusing on key clinical stage products in the mid to late phases.

BD Technology Platforms: Actively exploring collaboration and development of early-stage products with AI pharmaceuticals, nucleic acid drug antigen screening platforms, gene therapy technologies, novel vaccine development platforms, and intratumoral injection technology platform.

Internationalization of BD: Pursuing a dual strategy of both licensing in and out, expanding international projects with leading multinational pharmaceutical companies and Belt and Road initiatives, reinforcing strategic relationships with fund institutions having overseas resources, and advancing the connection and collaboration of global projects.

BD Ecosystem Construction : BD Ecosystem Construction: Leveraging the advantages of group clinical development, product registration, and commercialization resources, adopting a Pharma+Biotech win-win model, engaging in extensive and in-depth collaboration with Biotech companies or research institutions that possess innovative advantages, including practical and feasible merger and acquisition models, to continue supporting the group's external innovation.



BD Work Completion Status in 3 years

License-out:

- Granted the development and commercialization rights of SYS6002 (Nectin-4 ADC) to Corbus Pharmaceuticals outside of Greater China.
- Granted the development and commercialization rights of SYSA1801 (Claudin 18.2 ADC) to Elevation Oncology outside of Greater China.

License-in:

- Obtained the exclusive rights to develop and commercialize the anti-IL-4R α monoclonal antibody CM310 and anti-TSLP monoclonal antibody CM326 in Mainland of China from KeyMed Biosciences
- Obtained the exclusive rights to develop and commercialize anti-HER2 bispecific antibody KN026 in Mainland of China for the indication of breast cancer and gastric cancer from Alphamab Oncology
- Acquired the equity of CSPC Recomgen Pharmaceutical (Guangzhou) Co., Ltd. to 83.96%
- Acquired exclusive rights to develop, manufacture and commercialize HBM9161, Harbour BioMed's FcRn inhibitor, in Greater China
- Obtained the exclusive commercialization rights of Haihe Biopharmaceutical's c-Met inhibitor Glumetinib Tablets in Greater China
- Obtained exclusive authorization from Pfizer to launch Paxlovid, a localized oral antiviral treatment drug in China



BD Key Therapeutic Area Strategy for 2024

Reinforce Leading Position in Established Areas


- Comprehensive Management of Stroke Disease, with a Focus on the Strategic Positioning and Collaboration of Innovative Drug Projects in Vascular Recanalization, Neuroprotection, and Anti-Inflammation that Synergize with the Company's Existing Resources
- Attention to Late-stage Clinical or Newly Approved Drugs in the Alzheimer's Disease (AD) Field, as well as Emerging Novel Targeted Therapeutics.

Neurology Field



- Strengthen differentiation in hematologic malignancies, lung cancer, and breast cancer, focusing on targeted therapies, new immunotherapies, and combination treatments.
- Explore innovative drugs in areas such as digestive tract tumors, gynecological tumors, and urological tumors.
- .

Oncology Field



- Focus on challenging areas like refractory hypertension, hyperlipidemia, heart failure and anticoagulant. Pay attention to long-acting, oral diabetes/weight reduction innovative products.
- Address thyroid diseases and innovative treatments related to gout.

Cardiovascular & Endocrinology Field



- Emphasize areas like idiopathic pulmonary fibrosis (IPF), COPD/asthma, bronchiectasis and cough, exploring innovative targets, drug-device combinations, and drug delivery systems.
- Focus on high-end antibiotics effective against clinically resistant bacteria.
- Address conditions such as atopic dermatitis, systemic lupus erythematosus, and inflammatory bowel disease (IBD).

Respiratory, Autoimmune & Anti-Infective Field



Explore Novel Therapeutic Areas and Technology Platforms

- Address primary and secondary kidney diseases like IgA nephropathy and diabetic nephropathy.
- Focus on complications of kidney diseases like renal anemia, hyperphosphatemic kidney disease, hypertension, and kidney-related itching.

Nephrology Field



- Concentrate on well-established companies with mature late-stage ophthalmology pipelines.
- Focus on products for eye diseases like AMD using new targets, new dosage forms, long-acting formulations, nanomedicines, and gene therapies, with a special focus on geographic atrophy indications.

Ophthalmology Field



- Focus on therapeutic nuclear medicine, breaking through new targets, new indications, and new isotopes while avoiding homogenization.
- Focus on larger market opportunities in solid tumor such as prostate cancer, lung cancer, breast cancer, gastrointestinal tumors under new nuclides and new target combination

Nuclear Medicine Field



- Expand into major population-based psychiatric disorders like depression and schizophrenia, focusing on the layout and collaboration of novel targeted drugs with improved efficacy, safety, and compliance.
- Emphasize fast-acting nasal spray formulations.

Psychiatry Field



- Chronic Pain: Focus on innovative drug projects that provide better pain relief, higher safety, and non-addictive properties.
- Acute Pain: Concentrate on innovative projects that extend postoperative pain relief duration while maintaining higher safety.

Pain Management Field



- Focus on unmet clinical needs in orthopedics, from completely innovative products to products that improve patient accessibility, and tap opportunities in orthopedics
- Focus on spine surgery-related drugs, osteoporosis iterations


Orthopedics Field



Aim to Become an ESG Leader in Pharmaceutical Industry

2023 Environmental Protection Key Dates

*The emission reduction target is based on the emission in 2017



◆ Achieve the 2025 goal ahead of schedule in 2023

Investment in environmental protection upgrading in 2023


RMB100M

To support the upgrade of environment protection center per year


RMB760M

Invested in smart manufacturing, equipment upgrade and modification

- ◆ Ouyi, NBP, CSPC Innovation, Factory in Taizhou (subsidiaries) are recognized as “Green Factories” by the MIIT, Yinhu, Weisheng, Shengxue and Baike were recognized and publicized by the provincial and municipal "green manufacturing enterprises in 2024.
- ◆ Achieved “Five Zeros and One Low”: zero cases of death, serious injuries, multiple injuries, occupational disease and poisoning incident as well as low incident rate of minor injuries



Continuous MSCI ESG rating upgrade



Social assistance project in 2023

- Patient assistance : 84 people
- Employee assistance : 81 people
- Education Assistant Fund: 2024 people
- Charity drug donation: 59300 people



E-mail Address of CSPC IR Team:

ir@cspc.hk

Thanks!